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Background: Evidence indicates that the serum concentration of uric acid (UA) in patients may relate both 
to the pathophysiology and therapeutics of bipolar disorder (BPD). The purpose of this study was to 
examine the changes and clinical significance of serum UA concentrations in first-episode manic patients 
suffering from BPD. Methods: Seventy-six drug-naive patients with first-episode bipolar mania and 76 age-
and gender-matched healthy subjects were recruited. Young Mania Rating Scale and Hamilton Depression 
Rating Scale were used to assess clinical symptoms. We tested serum UA concentrations by sandwich 
enzyme-linked immunosorbent assay at baseline and at the end of 8-week treatment in BPD patients and 
in the control group. Results: After 8-week quetiapine and sodium valproate treatment, this study revealed 
that the serum UA concentrations in remitted patients were significantly lower than nonremitted patients; 
however, those remitted patients still had higher serum UA than healthy controls. We discovered that the 
baseline UA concentration was higher in nonremitted than remitted patients after 8 weeks of treatment. 
Finally, a positive association was found between serum UA and symptom relief in the first episode of 
manic disorder patients. Conclusion: Patients with first-episode BPD had high levels of serum UA, which 
responds to treatment mainly in remitted patients. Our results suggest that serum UA concentrations 
might present potentially a trait marker in bipolar patients. 
Disciplines 
Medicine and Health Sciences 
Publication Details 
Chen, J., Zhang, L., Liu, K., Chen, H., Zhou, S., Wang, N., Tan, Y., Wang, S., Jones, A., Yang, F. & Huang, X. 
(2019). Patients with drug-naive bipolar disorder in remission after 8 weeks of treatment had decreased 
serum uric acid concentrations. Frontiers in Psychiatry, 10 767-1-767-8. 
Authors 
Jingxu Chen, Ligang Zhang, Ke-Zhi Liu, Hongmei Chen, Shuang-Jiang Zhou, Ning Wang, Yun-Long Tan, 
Shao-Li Wang, Alison L. Jones, Fu-De Yang, and Xu-Feng Huang 
This journal article is available at Research Online: https://ro.uow.edu.au/ihmri/1491 
1Edited by: 
Manit Srisurapanont, 
Chiang Mai University, 
Thailand
Reviewed by: 
Natalia P. Rocha, 
University of Texas Health Science 
Center at Houston, 
United States 
Alessandra Maria Passarotti, 
University of Illinois at Chicago, 
United States
*Correspondence: 
Xu-Feng Huang 
xhuang@uow.edu.au 
Fude Yang 
yangfd200@126.com
†These authors have contributed 
equally to this work
Specialty section: 
This article was submitted to 
 Psychopathology, 
 a section of the journal 
 Frontiers in Psychiatry
Received: 09 May 2019
Accepted: 24 September 2019
Published: 31 October 2019
Citation: 
Chen J-X, Zhang L-G, Liu K-Z, 
Chen H-M, Zhou S-J, Wang N, 
Tan Y-L, Wang S-L, Jones A, 
Yang F-D and Huang X-F (2019) 
Patients With Drug-Naive Bipolar 
Disorder in Remission After 8 Weeks 
of Treatment Had Decreased Serum 
Uric Acid Concentrations. 
 Front. Psychiatry 10:767. 
 doi: 10.3389/fpsyt.2019.00767
Patients With Drug-Naive Bipolar 
Disorder in Remission After 8 Weeks 
of Treatment Had Decreased Serum 
Uric Acid Concentrations
Jing-Xu Chen 1†, Li-Gang Zhang 1†, Ke-Zhi Liu 2, Hong-Mei Chen 1, Shuang-Jiang Zhou 1, 
Ning Wang 1, Yun-Long Tan 1, Shao-Li Wang 1, Alison Jones 3, Fu-De Yang 1* and Xu-Feng Huang 3*
1 Beijing Hui-Long-Guan Hospital, Peking University, Beijing, China, 2 Department of Psychiatry, The Affiliated Hospital of 
Southwest Medical University, Luzhou, China, 3 Illawarra Health and Medical Research Institute and School of Medicine, 
University of Wollongong, Wollongong, NSW, Australia
Background: Evidence indicates that the serum concentration of uric acid (UA) in patients 
may relate both to the pathophysiology and therapeutics of bipolar disorder (BPD). The 
purpose of this study was to examine the changes and clinical significance of serum UA 
concentrations in first-episode manic patients suffering from BPD.
Methods: Seventy-six drug-naive patients with first-episode bipolar mania and 76 age- 
and gender-matched healthy subjects were recruited. Young Mania Rating Scale and 
Hamilton Depression Rating Scale were used to assess clinical symptoms. We tested 
serum UA concentrations by sandwich enzyme-linked immunosorbent assay at baseline 
and at the end of 8-week treatment in BPD patients and in the control group.
Results: After 8-week quetiapine and sodium valproate treatment, this study revealed that 
the serum UA concentrations in remitted patients were significantly lower than nonremitted 
patients; however, those remitted patients still had higher serum UA than healthy controls. 
We discovered that the baseline UA concentration was higher in nonremitted than remitted 
patients after 8 weeks of treatment. Finally, a positive association was found between 
serum UA and symptom relief in the first episode of manic disorder patients.
Conclusion: Patients with first-episode BPD had high levels of serum UA, which 
responds to treatment mainly in remitted patients. Our results suggest that serum UA 
concentrations might present potentially a trait marker in bipolar patients.
Keywords: bipolar disorder, hyperuricemia, mania, therapeutic efficacy, uric acid
INTRODUCTION
Bipolar disorder (BPD) is a severe and chronic mental disorder with a lifetime prevalence of 
approximately 1% to 2% in the general population (1). The disease is associated with a potentially 
devastating impact on individual well-being including social, occupational, and general functioning 
(2–4). Drugs such as mood stabilizers, atypical antipsychotics, and nondrug therapy, including 
Abbreviations: BMI, body mass index; BP, blood pressure; BPD, bipolar disorder; CI, confidence interval; DSM-IV, Diagnostic 
and Statistical Manual of Mental Disorders, 4th Edition; FBG, fasting blood glucose; HDL-C, high density lipoprotein 
cholesterol; OR, odds ratio; SPSS, Statistical Package for the Social Sciences; UA, uric acid.
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electroconvulsive therapy, transcranial magnetic stimulation, and 
psychotherapy, are shown to have limited efficacy; the outcomes 
in a large number of patients are unsatisfactory (5–7). Therefore, 
the therapeutics of BPD remains an important challenge in 
psychiatry. This may be due to the underlying neurobiology of 
the diseases being still largely unclear. Improved understanding 
of the pathophysiological basis of BPD is required for the 
development of more targeted therapeutics.
Uric acid (UA) and purine regulate a number of brain 
activities such as cognition, memory, and mood and highly 
exist in the limbic regions and basal ganglia of brain (8). These 
brain regions have been reported to have some abnormalities in 
BPD through neuroimaging studies (9, 10). Growing evidence 
from genetic and clinical studies suggested the purinergic 
system might be a contributing factor in the pathophysiology 
of BPD (8). The purinergic system includes signaling 
pathways of the neurotransmitter adenosine triphosphate and 
the neuromodulator adenosine. Agonists of adenosine are 
considered to have sedative, anticonvulsant, antiaggressive, and 
antipsychotic properties, whereas its antagonists, for example, 
caffeine, may cause irritability and disrupt the sleep–wake 
cycle, which is a common precipitant for manic relapse (11). 
In addition, adenosinergic dysfunction is found in euthymic 
patients with BPD, and there is a significant association between 
higher functioning impairment and lower concentrations of 
adenosine in blood (12).
UA is a purine metabolite produced by the xanthine 
oxidoreductase from xanthine or hypoxanthine. Peripheral 
and central UA concentrations are highly correlated (13). 
An increased serum UA concentration could be due to the 
result of amplified purinergic turnover or reduced adenosine 
transmission (14, 15). Over the past decades, several studies 
have shown that BPD patients in all phases (manic/hypomanic, 
mixed depressed, or euthymic) could have an increased serum 
UA concentration, as compared with healthy or other mental 
disorder subjects (16–20). These studies have indicated altered 
regulation of purinergic system in BPD (21). However, no 
significant differences in serum UA levels were also reported 
between euthymic BPD and healthy subjects (12, 20, 22, 23). 
Also, no significant differences were found in serum UA between 
the patients with manic episodes and euthymic status (20, 24, 
25). Therefore, whether an elevated UA concentration might be 
a trait marker for BPD remains to be determined.
A positive correlation was reported between serum UA levels 
and symptom severity in mania patients (18, 19, 26). In line with 
their study, a combinational therapy of valproate together with 
allopurinol (hyperuricemia-lowering drug) results in significant 
improvements in patients suffering from acute mania (27, 28). In 
contrast, no improvement was also reported by using allopurinol 
in treating manic symptoms (29, 30). Also, similar UA levels 
between manic state and remitted state were reported (20, 24).
In consideration of controversial data from literature, we 
carried out a cohort study on first-episode and drug-naive manic 
patients and investigated whether (1) serum UA concentrations 
differ among manic episode, remission after treatment, and 
healthy subjects, matched for age and gender; (2) treatment with 
an atypical antipsychotic drug (quetiapine) and mood stabilizer 
(sodium valproate) affects the serum UA concentrations in 
manic patients; and (3) there is any relationship between serum 
UA concentration and the therapeutic efficacy.
MeTHODS
Subjects
Seventy-six inpatients were recruited from inpatients suffering 
BPD. The study was conducted from January 2015 to December 
2017 in Beijing Hui-Long-Guan Hospital, affiliated with Clinical 
Medical College of Peking University, China. The inclusion 
criteria were subjects between 18 and 45 years old, diagnosis of a 
manic/hypomanic episode by the consensus of two independent 
senior psychiatrists according to the Diagnostic and Statistical 
Manual of Mental Disorders, Fourth Edition criteria (31), and 
first-episode and never-treated history, which was confirmed by 
collateral histories from family members. All subjects were Han 
Chinese. The patients with a history of affective disorder and 
other Axis I diagnoses such as schizophrenia and neurological 
illness were excluded from this study.
The control group had 76 healthy subjects and was recruited 
from the local community, matched with the patients for age 
and gender. Healthy subjects were 18 to 45 years of age without 
any record of personal or family history of psychiatric disorders 
and were Han Chinese. All participants were without any 
record of organic brain diseases, cardiovascular disease, chronic 
inflammatory disease, diabetes, nephropathy, and gout or other 
diseases associated with changes in serum UA concentrations, as 
determined by a complete medical history, physical examination, 
and laboratory tests. Neither bipolar patients nor control subjects 
were taking drugs or medications, none had alcohol abuse/
dependence, and none were pregnant/breastfeeding, which 
could influence UA concentrations.
All subjects gave signed and informed consent that was 
approved by the institutional review board of the Beijing Hui-
Long-Guan Hospital, Peking University.
All patients received the combination quetiapine (606.58 ± 
150.85 mg, daily) plus sodium valproate (1,077.97 ± 338.77 mg, 
daily) treatment for 8 weeks, which was in agreement with the 
first-line treatment of mania in international evidence-based 
guidelines (32).
Assessment
Psychopathological symptoms of patients were assessed on the 
day of blood sampling by four psychiatrists who were blind to 
the clinical status and treatment conditions. Young Mania Rating 
Scale (YMRS) (33) was used to measure the severity of manic 
symptoms before and after treatment. YMRS and the 17-item 
version of the Hamilton Depression Rating Scale (HDRS) (34) 
were used to confirm the remission during the recovery period. 
The patients in remission were defined by both YMRS and HDRS 
scores being ≤7. To ensure consistency and reliability of ratings, 
before undertaking the study, four psychiatrists who worked over 
5 years in clinical practice simultaneously received a training 
session on how to use YMRS and HDRS, ensuring a correlation 
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coefficient maintained greater than 0.8 by repeated assessments 
across the study.
The blood samples from all subjects were taken between 6 and 
7 after overnight fasting as baseline and were taken again after 8 
weeks of treatment between 6 and 7. Serum UA concentrations 
were assessed using sandwich enzyme-linked immunosorbent 
assay, which was by a commercially available kit (DRG kit cat. no. 
EIA-2925, Germany). The parameters potentially affecting serum 
UA concentrations such as metabolic parameters (triglycerides, 
high-density lipoprotein cholesterol, and fasting blood glucose) 
and kidney function (creatinine, urea) were also measured. The 
height, body weight, and blood pressure of all subjects were 
measured. Body mass index (BMI) was calculated as body weight 
in kilograms divided by height in meters squared. Hyperuricemia 
was defined as serum level of UA >420 µmol/l (7.0 mg/dl) for men 
and >360 µmol/l (6.0 mg/dl) for women (17). Current smoking 
referred to smoking at least one cigarette per day over the last 1 
month before enrollment.
Statistical Analysis
The differences of demographic data between patients and 
controls were analyzed by χ2 test or independent-samples t test, 
wherever it is appropriate. The paired t test was used to compare 
serum UA concentrations, YMRS scores, and HDRS scores 
between the baseline and posttreatment in the patient group. 
The paired t test was also used to compare serum UA levels 
in drug-naive manic patients and patients in remission after 
treatments. Pearson correlation coefficient was used to evaluate 
the relationship between serum UA levels and YMRS scores 
when data were in normal distribution. Independent-samples 
t test was applied to single-time-point data. When significant 
differences were detected, covariant analysis controlling for 
BMI, age, and sex and Bonferroni post hoc analyses for multiple 
comparisons were applied. Results are expressed as mean ± SD. 
All statistical tests were two-tailed, and p < 0.05 was considered 
as statistically significant. Statistical analyses were performed 
using SPSS (version 17.0).
ReSUlTS
Demographic and clinical characteristics of the study population 
are shown in Table 1. Patients and controls were matched with 
respect to age and gender. There were no significant differences 
in demographic and clinical characteristics (Table 1). Sixty-
eight cases were mania (39 men and 29 women), and the other 
eight cases were hypomania (five men and three women). 
No differences in the levels of serum UA between mania and 
hypomania patients (379.74 ± 99.25 vs 368.50 ± 103.70 µmol/l, 
t = 0.34, p = 0.74).
After 8 weeks of quetiapine and sodium valproate treatment, 
YMRS scores (t = 25.76 p < 0.01) and serum UA concentrations 
(t = 3.36, p = 0.01) were lower compared to baselines (Table 2, 
Figure 1). Fifty-three patients reached remission status according 
to the scores of YMRS and HDRS. We detected that the serum UA 
concentrations were significantly lower in the remission group 
compared to nonremission group both at baseline (361.89  ± 
92.36 vs 416.96 ± 105.31 µmol/l, t = 2.29, p = 0.03) and after 8 
weeks of treatment (323.57 ± 73.53 vs 364.57 ± 91.98 µmol/l, 
t = 2.07, p = 0.04) (Figure 2). These differences remained after 
controlling for age, gender, and BMI (all p < 0.05).
Pearson correlation analysis showed that serum UA 
concentrations were not correlated with severity of symptoms, 
which were assessed by YMRS at both baseline (r = 0.18, p = 
0.12) and at the end of 8 weeks of treatment (r = 0.21, p = 0.07). 
However, there was a significant correlation between changes in 
serum UA concentrations and that of the change of the YMRS 
scores after treatments (pretreatment − posttreatment, r = 0.25, 
p = 0.03; Figure 3). The correlations remained significant after 
controlling for the baseline YMRS score and UA levels (r = 0.23, 
p = 0.047).
The prevalence rate of hyperuricemia between the remitted 
patients and healthy controls did not differ (17.0% and 10.5%, 
χ2 = 1.14, p = 0.29). The prevalence rate of hyperuricemia in all 
patients at baseline was 40.9%, which was significantly higher 
than the remitted patients and healthy controls (χ2 = 18.25, p < 
0.01; and χ2 = 8.27, p < 0.01, respectively). A paired-sample t test 
TABle 1 | Demographic and clinical characteristics of drug-naive patients with first-episode manic patients and healthy controls.
Variable Manic patients (n = 76) Healthy controls (n = 76) χ2/t p
Age (y) 26.34 ± 8.16 26.95 ± 6.67 0.45 0.65
Gender, male, n (%) 43 (56.6) 43 (56.6) 0.00 1.00
Education (y) 12.14 ± 3.33 12.74 ± 3.40 1.08 0.28
Marital status, married, n (%) 32 (42.1) 28 (36.8) 0.44 0.51
Duration of illness (d) 37.26 ± 52.43 —
Current smoking, n (%) 16 (21.1%) 9 (11.8%) 2.35 0.13
BMI kg/m2 22.14 ± 2.54 21.97 ± 2.38 0.44 0.66
Systolic BP (mm Hg) 109.34 ± 11.98 107.83 ± 9.77 0.85 0.40
Diastolic BP (mm Hg) 73.22 ± 7.99 73.16 ± 8.24 0.05 0.96
HDL-C (mmol/l) 1.32 ± 0.36 1.33 ± 0.46 0.08 0.94
TG (mmol/l) 1.24 ± 0.87 1.28 ± 0.65 0.33 0.74
FBG (mmol/l) 4.71 ± 0.67 4.68 ± 0.58 0.30 0.76
Urea (mmol/l) 4.56 ± 1.31 4.24 ± 0.96 1.76 0.08
Creatinine (µmol/l) 74.62 ± 18.61 70.04 ± 15.86 1.63 0.11
UA (µmol/l) 378.55 ± 99.08 293.39 ± 71.40 6.22 < 0.01
BMI, body mass index; BP, blood pressure; HDL-C, high-density lipoprotein cholesterol; TG, triglyceride; FBG, fasting blood glucose levels.
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revealed that serum UA levels of the remitted patients were 
significantly higher than these patients in drug-naive phase 
(Tables 1 and 2, t = 2.71, p < 0.01). Independent-samples t test 
showed that serum UA levels in healthy controls were lower than 
first-episode drug-naive patients (Table 1, t = 6.22, p < 0.01) 
and the remitted patients after 8-week treatments (t = 2.49, p = 
0.01; Figure 4). Covariance analysis showed that the serum UA 
differences between healthy controls and manic patients and 
remitted patients remained statistically significant after adjusting 
for gender, age, and BMI (all p < 0.01; Table 1 and Figure 4).
DISCUSSION
This study analyzed the relationship of system levels of UA to 
measures of YMRS and HDRS in first-episode manic patients 
suffering from BPD prior and after 8-week quetiapine and 
sodium valproate treatment. Our results revealed that the serum 
UA levels in remitted patients were significantly lower than 
nonremitted patients, although they were still had higher than 
healthy controls. Furthermore, we showed that the baseline UA 
was significantly higher in nonremitted than remitted patients 
after 8 weeks of treatment. Also, a positive association was found 
between serum UA and symptom relief in these patients.
In the past few years, a number of studies have investigated 
the changes of UA in patients suffering BPDs; however, the data 
are inconsistent and even controversial (20, 22, 35, 36). This 
may be due to various confounders involved in studies because 
the nature of BPD is a complex, chronic, and heterogeneous 
psychiatric disease (37). Two studies have investigated serum 
UA levels in first-episode manic patients with the sample sizes 
of 20 based on the criteria of Diagnostic and Statistical Manual 
of Mental Disorders, Fourth Edition and 31 based on the criteria 
of International Classification of Diseases, 10th Revision (26, 38). 
Both studies have had relatively small sample size without taking 
into consideration of confounders such as the levels of creatinine, 
cholesterol, and glucose and BMI, which could have influenced 
UA levels (39, 40). We conducted a prospective study on a cohort 
of 68 first-episode manic patients controlling for potential 
confounders including metabolic and kidney function–related 
variables. From this study, we suggest that a possible contributing 
factor could be due to discrepancy of baseline levels of UA in the 
BPD patient cohort studied.
Overall, recent studies support that the patients suffering 
BPD at manic phase have significantly higher levels of serum UA 
during both acute and chronic phases compared with healthy 
controls (24, 28, 38, 41). Also, the serum UA levels were higher in 
mania phase than depression and remission phases in the same 
patients suffering from BPD (19, 25, 42). Consistent with these 
results, our study showed that first-episode drug-naive patients 
in manic phase had significantly higher serum UA than those of 
patients in remission and healthy controls. Therefore, we support 
that increased UA levels were associated with a state of manic 
episode, which may be used as a routine check in the manic 
phase of BPD (13).
Psychotropic and antipsychotic drugs could have different 
effects on serum UA levels. Lithium and carbamazepine reduce 
UA serum levels (43, 44). Zotepine reduces UA levels more 
than risperidone and haloperidol (45, 46). Conversely, it has 
been reported that olanzapine increases UA levels in moderate 
mania (47, 48). The present study observed that bipolar patients 
in mania phase treated with quetiapine and valproate decreased 
serum UA, which was in consistence with a report of a previous 
study (18). Previous study showed that adjunctive allopurinol 
reduces UA and increases remission rate in manic patients 
(49). Similarly, we found that decreased UA was in parallel 
with an improvement of YMRS scores in mania patients. It was 
possible that UA may have contributed to the severity of mania 
symptoms, while reduced UA helped relief of manic symptoms. 
One explainable mechanism was that alleviated oxidative stress 
by lowering UA may have led to the effect of antimanic drug 
because an elevated UA is known to induce oxidative stress, 
which may worsen the pathophysiology of manic disorder 
(50–53).
The present study was the first to investigate the serum UA 
levels in patients suffering from the first manic episode who 
FIgURe 1 | Serum UA concentarion from baseline over 8 weeks of treatment. 
*p < 0.05.
TABle 2 | Serum UA levels, YMRS scores, and HDRS scores among bipolar 
patients receiving treatment for 8 weeks.
Variable Baseline Week 8 t p
UA (µmol/l) 378.55 ± 99.08 335.97 ± 81.18 3.361 0.01
YMRS scores 27.47 ± 5.23 6.44 ± 5.73 25.76 <0.01
HDRS scores 3.11 ± 3.04 4.01 ± 4.14 −1.615 0.11
UA, uric acid; YMRS, Young Mania Rating Scale; HDRS, Hamilton Depression 
Rating Scale.
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have achieved remission after 8 weeks of treatment. We found 
that serum UA levels in remitted patients were higher than those 
in healthy controls after adjusting for age, gender, and BMI, 
which supported the idea that altered purinergic regulation may 
be involved in the genesis of BPD (19, 21, 24, 54). In addition, 
several studies have reported higher levels of UA in the depressive 
episodes of BPD compared with healthy controls (19, 24, 54). 
Therefore, an increased UA may be a predisposition in bipolar 
patients as a trait marker, which is independent of some current 
or past affective episodes. On the other hand, it was noted that 
some euthymic patents had similar UA levels as healthy controls 
particularly if the patients had a longer duration of illness, high 
number of affected mood episodes, and longer mood stabilizer 
exposure (12, 20, 22, 23).
The present study had several limitations. First, our data should 
be seen as a pilot study instead of generalized clinical evidence 
or relevance because our study had relatively small sample size, 
especially of female patients from one district of China. Second, 
bipolar patients with depressive episodes or recurrent episodes 
(possibly with years of pharmacological intervention) were not 
enrolled in this study. Third, the prevalence of cigarette smoking 
was normally higher in patients with BPD than healthy controls, 
but how smoking affects serum UA in BPD patients is still largely 
unknown (55, 56). Fourth, all inpatients had the same dietary 
profile; however, healthy subjects might have a different dietary 
profile, which could affect the comparison of serum UA between 
patients and healthy controls (57). Lastly, only one time point in 
remission was checked; thus, the time course of UA response to 
therapy remains unknown.
CONClUSIONS
Bipolar patients at the first-episode drug-naive phase had 
significantly higher levels of serum UA. Patients in remission after 
8 weeks of treatment had significantly reduced serum UA, while 
it was still higher than healthy controls. Patients in nonremission 
after 8 weeks of treatment had significantly less reduction in 
serum UA compared with those of remitted patients. Therefore, 
high levels of serum UA were a pathological condition of bipolar 
disease at manic phase, contributed to the severity of symptoms, 
and were reduced in remitted patients, but not in nonremitted 
patients. Furthermore, serum UA levels might be potentially a 
trait marker in bipolar patients.
FIgURe 3 | Correlation between changes in serum UA levels and that in 
YMRS scors after treatment (r = 0.25, p = 0.03).
FIgURe 2 | Serum UA levels R-BP (n = 53) and NR-BP (n = 23) at baseline (left panel) and after treatment (right panel). R-BP, remitted bipolar patients; NR-BP, non-
remitted bipolar patients. *p < 0.05.
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